FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Fumiaki Ikeda

Research Profile

Chemicals & Drugs

Procedures

Microbial Sensitivity Tests

Living Beings

Disorders

Physiology

Fungal Drug Resistance

Concepts & Ideas

Structure-Activity Relationship

Co-author Network

Publications

TOP 3
Kyoko Niimi; Masakazu Niimi; Keigo Ueno; Matthew A Woods; Richard D Cannon; Hiroji Chibana; Kazuaki Hatakenaka; Fumiaki Ikeda; Katsuyuki Maki; Hironobu Nakayama; Brian C Monk
Reconstitution of high-level micafungin resistance detected in a clinical isolate of Candida glabrata identifies functional homozygosity in glucan synthase gene expression.
Kyoko Niimi; B C Monk; A Hirai; K Hatakenaka; T Umeyama; Erwin Lamping; Katsuyuki Maki; Koichi Tanabe; T Kamimura; Fumiaki Ikeda; Yoshimasa Uehara; R Kano; A Hasegawa; Richard D Cannon; Masakazu Niimi
Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity.
Katsuyuki Maki; Satoru Matsumoto; Etsuko Watabe; Yumi Iguchi; Masaki Tomishima; Hidenori Ohki; Akira Yamada; Fumiaki Ikeda; Shuichi Tawara; Seitaro Mutoh
Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Fumiaki Ikeda (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Kyoko Niimi; Masakazu Niimi; Keigo Ueno; Matthew A Woods; Richard D Cannon; Hiroji Chibana; Kazuaki Hatakenaka; Fumiaki Ikeda; Katsuyuki Maki; Hironobu Nakayama; Brian C Monk
Reconstitution of high-level micafungin resistance detected in a clinical isolate of Candida glabrata identifies functional homozygosity in glucan synthase gene expression.
The Journal of antimicrobial chemotherapy 2012;67(7):1666-76.
2010: Kyoko Niimi; B C Monk; A Hirai; K Hatakenaka; T Umeyama; Erwin Lamping; Katsuyuki Maki; Koichi Tanabe; T Kamimura; Fumiaki Ikeda; Yoshimasa Uehara; R Kano; A Hasegawa; Richard D Cannon; Masakazu Niimi
Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity.
The Journal of antimicrobial chemotherapy 2010;65(5):842-52.
2008: Katsuyuki Maki; Satoru Matsumoto; Etsuko Watabe; Yumi Iguchi; Masaki Tomishima; Hidenori Ohki; Akira Yamada; Fumiaki Ikeda; Shuichi Tawara; Seitaro Mutoh
Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds.
Microbiology and immunology 2008;52(8):383-91.
2008: Masaki Tomishima; Hidenori Ohki; Akira Yamada; Katsuyuki Maki; Fumiaki Ikeda
Novel echinocandin antifungals. Part 2: Optimization of the side chain of the natural product FR901379. Discovery of micafungin.
Bioorganic & medicinal chemistry letters 2008;18(9):2886-90.
2008: Masaki Tomishima; Hidenori Ohki; Akira Yamada; Katsuyuki Maki; Fumiaki Ikeda
Novel echinocandin antifungals. Part 1: novel side-chain analogs of the natural product FR901379.
Bioorganic & medicinal chemistry letters 2008;18(4):1474-7.
2008: Shinobu Takeda; Toru Nakai; Fumiaki Ikeda; Kazuo Hatano
Overproduction of a metallo-beta-lactamase by a strong promoter causes high-level imipenem resistance in a clinical isolate of Pseudomonas aeruginosa.
Chemotherapy 2008;54(3):181-7.
2007: Shinobu Takeda; Toru Nakai; Yoshimi Wakai; Fumiaki Ikeda; Kazuo Hatano
In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 2007;51(3):826-30.
2007: Katsuyuki Maki; Ann R Holmes; Etsuko Watabe; Yumi Iguchi; Satoru Matsumoto; Fumiaki Ikeda; Shuichi Tawara; Seitaro Mutoh
Direct comparison of the pharmacodynamics of four antifungal drugs in a mouse model of disseminated candidiasis using microbiological assays of serum drug concentrations.
Microbiology and immunology 2007;51(11):1053-9.
2007: Fumiaki Ikeda; Shigeki Tanaka; Hidenori Ohki; Satoru Matsumoto; Katsuyuki Maki; Masataka Katashima; David Barrett; Yoshiyasu Aoki
Role of micafungin in the antifungal armamentarium.
Current medicinal chemistry 2007;14(11):1263-75.
2006: Kyoko Niimi; Katsuyuki Maki; Fumiaki Ikeda; Ann R Holmes; Erwin Lamping; Masakazu Niimi; Brian C Monk; Richard D Cannon
Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility.
Antimicrobial agents and chemotherapy 2006;50(4):1148-55.
2006: Katsuyuki Maki; Etsuko Watabe; Yumi Iguchi; Hideko Nakamura; Masaki Tomishima; Hidenori Ohki; Akira Yamada; Satoru Matsumoto; Fumiaki Ikeda; Shuichi Tawara; Seitaro Mutoh
Determination of antifungal activities in serum samples from mice treated with different antifungal drugs allows detection of an active metabolite of itraconazole.
Microbiology and immunology 2006;50(4):281-92.
2003: Etsuko Watabe; Toru Nakai; Satoru Matsumoto; Fumiaki Ikeda; Kazuo Hatano
Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability.
Antimicrobial agents and chemotherapy 2003;47(6):1995-8.
2003: Toru Nakai; Jun Uno; Fumiaki Ikeda; Shuichi Tawara; Kazuko Nishimura; Makoto Miyaji
In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.
Antimicrobial agents and chemotherapy 2003;47(4):1376-81.
2002: T Nakai; Jun Uno; K Otomo; Fumiaki Ikeda; Shuichi Tawara; T Goto; Kazuhiro Nishimura; Makoto Miyaji
In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds.
Chemotherapy 2002;48(2):78-81.
2002: Kazuo Hatano; Yoshihiko Morishita; Toru Nakai; Fumiaki Ikeda
Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus.
The Journal of antibiotics 2002;55(2):219-22.
2001: David Barrett; Akira Tanaka; Etsuko Watabe; Katsuyuki Maki; Fumiaki Ikeda
Novel amidine conjugates of the ornithine moiety of the macrocyclic antifungal lipopeptidolactone FR901469.
The Journal of antibiotics 2001;54(10):844-7.
2001: Y Matsumoto; A Ikemoto; Yoshimi Wakai; Fumiaki Ikeda; Shuichi Tawara; K Matsumoto
Mechanism of therapeutic effectiveness of cefixime against typhoid fever.
Antimicrobial agents and chemotherapy 2001;45(9):2450-4.
2001: David Barrett; Akira Tanaka; K Harada; Etsuko Watabe; Katsuyuki Maki; Fumiaki Ikeda
Synthesis and biological activity of novel macrocyclic antifungals. modification of the tyrosine moiety of the lipopeptidolactone FR901469.
Bioorganic & medicinal chemistry letters 2001;11(14):1843-9.
2001: David Barrett; Akira Tanaka; K Harada; Hidenori Ohki; Etsuko Watabe; Katsuyuki Maki; Fumiaki Ikeda
Synthesis and biological activity of novel macrocyclic antifungals: acylated conjugates of the ornithine moiety of the lipopeptidolactone FR901469.
Bioorganic & medicinal chemistry letters 2001;11(4):479-82.
2000: Satoru Matsumoto; Yoshimi Wakai; Toru Nakai; Kazuo Hatano; T Ushitani; Fumiaki Ikeda; Shuichi Tawara; T Goto; F Matsumoto; S Kuwahara
Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.
Antimicrobial agents and chemotherapy 2000;44(3):619-21.
2000: Fumiaki Ikeda; Yoshimi Wakai; Satoru Matsumoto; Katsuyuki Maki; Etsuko Watabe; Shuichi Tawara; T Goto; Y Watanabe; F Matsumoto; S Kuwahara
Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.
Antimicrobial agents and chemotherapy 2000;44(3):614-8.
2000: Shuichi Tawara; Fumiaki Ikeda; Katsuyuki Maki; Y Morishita; K Otomo; N Teratani; T Goto; Masaki Tomishima; Hidenori Ohki; Akira Yamada; Kohji Kawabata; Hisashi Takasugi; Kazuo Sakane; H Tanaka; F Matsumoto; S Kuwahara
In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.
Antimicrobial agents and chemotherapy 2000;44(1):57-62.
1997: S Matsumoto; Y Washizuka; Y Matsumoto; Shuichi Tawara; Fumiaki Ikeda; Y Yokota; M Karita
Appearance of a metronidazole-resistant Helicobacter pylori strain in an infected-ICR-mouse model and difference in eradication of metronidazole-resistant and -sensitive strains.
Antimicrobial agents and chemotherapy 1997;41(12):2602-5.
1997: S Matsumoto; Y Washizuka; Y Matsumoto; Shuichi Tawara; Fumiaki Ikeda; Y Yokota; M Karita
Induction of ulceration and severe gastritis in Mongolian gerbil by Helicobacter pylori infection.
Journal of medical microbiology 1997;46(5):391-7.